---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-091936"
form_type: "8-K"
ticker: null
cik: "0001626199"
company_name: "ALPINE IMMUNE SCIENCES, INC."
filed_at: "2024-04-10T23:59:59+00:00"
generated_at: "2026-06-04T00:25:14.352048+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 1.0
calibrated_materiality_score: 1.0
confidence: "high"
source: SEC EDGAR
---

# Vertex to acquire Alpine for $65/share (~$4.9B); deal expected to close Q2 2024

## Summary
- Total equity value ~$4.9B; Vertex will pay $65 per share in cash.
- Alpine’s lead drug povetacicept (dual BAFF/APRIL antagonist) showed best-in-class potential in IgA nephropathy; Phase 3 planned H2 2024.
- Stockholders owning ~25.5% of shares have agreed to tender; termination fee of $173M payable by Alpine under certain conditions.
- Transaction unanimously approved by both boards; expected to close in Q2 2024, subject to HSR and tender of majority of shares.
- Alpine’s pipeline includes studies in membranous nephropathy, lupus nephritis, and autoimmune cytopenias.

## SEC filing metadata
- accession: 0001193125-24-091936
- form_type: 8-K
- cik: 0001626199
- company_name: ALPINE IMMUNE SCIENCES, INC.
- filed_at: 2024-04-10T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 1.0
- calibrated_materiality_score: 1.0
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1626199/000119312524091936/0001193125-24-091936-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1626199/000119312524091936/d820872d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-091936
- JSON: https://secwatch.observer/filing/0001193125-24-091936.json
- Plain text: https://secwatch.observer/filing/0001193125-24-091936.txt

## Key facts
- Material Agreements
  ALPINE IMMUNE SCIENCES, INC. entered into Agreement and Plan of Merger with Vertex Pharmaceuticals Incorporated valued at $65.00 per share in cash, aggregate termination fee of $173 million (effective 2024-04-10).
  - Action: entry
  - Agreement: merger
  - Counterparty: Vertex Pharmaceuticals Incorporated
  - Value: $65.00 per share in cash, aggregate termination fee of $173 million
  - Effective: 2024-04-10
  source text: On April 10, 2024, Vertex Pharmaceuticals Incorporated, a Massachusetts corporation (“ Parent ”), Adams Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (“ Merger Sub ”), and Alpine Immune Sciences, Inc., a Delaware corporation (the “ Company ”) entered into an Agreement and Plan of Merger (the “ Merger Agreement ”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1626199/000119312524091936/0001193125-24-091936-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.